In this presentation you can see how diagnostic tests can provide patients suffering from NSCLC and their physicians with information about a tumour’s molecular profile, the likelihood of response to drug therapy and the most appropriate therapeutic options.
Tissue samples from the patient are first examined in the pathology laboratory to see whether cancer cells are present. If irregularities in cellular shape or structure are found, more extensive tests are required.
Specific cancer diagnosis
Roche has developed several immunohistochemistry and in situ hybridisation tests that reliably determine the type and subtype of lung tumour present.
The pathologist then characterises the tumour on the basis of cell differentiation and other criteria. Roche is currently developing a number of molecular biomarkers that will enable physicians to predict the course of cancers as accurately as possible.
A number of genes have been identified as growth drivers in non-small cell lung cancer (NSCLC). Tests from Roche help doctors understand the mechanisms driving tumour growth and thus to select drugs most likely to work best for a particular patient.
Several anticancer medicines offered by Roche play a crucial role in the treatment of lung cancer. And the company is currently developing additional new innovative drugs to address cancer-specific pathways and offer patients targeted therapies. In addition, Roche Diagnostics develops tests which would enable physicians to diagnose, stratify and to monitor responses to cancer treatment.
Roche’s Personalised Healthcare strategy allows to identify lung cancer patients with a specific genetic mutation who have incremental benefits from early treatment with targeted therapy.
Roche has also new test / compound combinations in development which would allow investigators to include patients with high levels of a specific gene-receptor in studies for the